PROPANC BIOPHARMA INC (PPCB) Fundamental Analysis & Valuation

NASDAQ:PPCB • US74346N7012

Current stock price

0.1032 USD
0 (-4.44%)
At close:
0.106 USD
+0 (+2.71%)
After Hours:

This PPCB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. PPCB Profitability Analysis

1.1 Basic Checks

  • In the past year PPCB has reported negative net income.
  • PPCB had a negative operating cash flow in the past year.
  • PPCB had negative earnings in each of the past 5 years.
  • In the past 5 years PPCB always reported negative operating cash flow.
PPCB Yearly Net Income VS EBIT VS OCF VS FCFPPCB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -1M -2M -3M -4M

1.2 Ratios

  • PPCB has a Return On Assets of -2147.26%. This is amonst the worse of the industry: PPCB underperforms 95.38% of its industry peers.
Industry RankSector Rank
ROA -2147.26%
ROE N/A
ROIC N/A
ROA(3y)-3739.99%
ROA(5y)-6299.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PPCB Yearly ROA, ROE, ROICPPCB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

  • PPCB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PPCB Yearly Profit, Operating, Gross MarginsPPCB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. PPCB Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, PPCB has more shares outstanding
  • Compared to 1 year ago, PPCB has a worse debt to assets ratio.
PPCB Yearly Shares OutstandingPPCB Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50K 100K 150K 200K 250K
PPCB Yearly Total Debt VS Total AssetsPPCB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 500K 1M 1.5M

2.2 Solvency

  • Based on the Altman-Z score of -1316.34, we must say that PPCB is in the distress zone and has some risk of bankruptcy.
  • PPCB has a worse Altman-Z score (-1316.34) than 95.18% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1316.34
ROIC/WACCN/A
WACCN/A
PPCB Yearly LT Debt VS Equity VS FCFPPCB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 -1M -2M -3M

2.3 Liquidity

  • PPCB has a Current Ratio of 0.00. This is a bad value and indicates that PPCB is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.00, PPCB is doing worse than 95.57% of the companies in the same industry.
  • A Quick Ratio of 0.00 indicates that PPCB may have some problems paying its short term obligations.
  • PPCB's Quick ratio of 0.00 is on the low side compared to the rest of the industry. PPCB is outperformed by 95.57% of its industry peers.
Industry RankSector Rank
Current Ratio 0
Quick Ratio 0
PPCB Yearly Current Assets VS Current LiabilitesPPCB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 1M 2M 3M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. PPCB Growth Analysis

3.1 Past

  • PPCB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.43%, which is quite impressive.
EPS 1Y (TTM)98.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. PPCB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PPCB. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PPCB Price Earnings VS Forward Price EarningsPPCB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PPCB Per share dataPPCB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -200 -400 -600

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PPCB Dividend Analysis

5.1 Amount

  • No dividends for PPCB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PPCB Fundamentals: All Metrics, Ratios and Statistics

PROPANC BIOPHARMA INC

NASDAQ:PPCB (3/27/2026, 8:00:01 PM)

After market: 0.106 +0 (+2.71%)

0.1032

0 (-4.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.81%
Inst Owner Change14.97%
Ins Owners55.59%
Ins Owner Change0%
Market Cap1.64M
Revenue(TTM)N/A
Net Income(TTM)-1.69M
AnalystsN/A
Price TargetN/A
Short Float %3.31%
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-703.62
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0
BVpS-0.26
TBVpS-0.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2147.26%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-3739.99%
ROA(5y)-6299.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0
Quick Ratio 0
Altman-Z -1316.34
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.92%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y18.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.4%
OCF growth 3YN/A
OCF growth 5YN/A

PROPANC BIOPHARMA INC / PPCB Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for PROPANC BIOPHARMA INC?

ChartMill assigns a fundamental rating of 0 / 10 to PPCB.


What is the valuation status of PROPANC BIOPHARMA INC (PPCB) stock?

ChartMill assigns a valuation rating of 0 / 10 to PROPANC BIOPHARMA INC (PPCB). This can be considered as Overvalued.


How profitable is PROPANC BIOPHARMA INC (PPCB) stock?

PROPANC BIOPHARMA INC (PPCB) has a profitability rating of 0 / 10.


Can you provide the financial health for PPCB stock?

The financial health rating of PROPANC BIOPHARMA INC (PPCB) is 0 / 10.